Page 186 - Genentech News Today

A research team led by gene editing pioneer David R. Liu, PhD, has published how it has applied the technology to develop a one-time treatment for spinal muscular atrophy (SMA) that showed effectiveness in cell and mouse models.

Welcome to the Litigation Gazette. Each quarter, BCLP's Paris team will keep you informed of the main litigation news in competition law, commercial litigation, labor law, IP/IT/Data...

Patients with asthma and specific eosinophil and IgE levels experienced greater improvements in exacerbations and FEV1 with dupilumab compared with other biologics, according to a study. These results indicate that dupilumab (Dupixent, Sanofi Genzyme/Regeneron) may be a better choice for patients who are eligible for multiple biologics, Ayobami T. Akenroye, MBChB, MPH, PhD, associate physician in

Once-monthly prophylactic fitusiran resulted in significantly fewer bleeding episodes compared with on-demand treatment among men with hemophilia A or B with or without inhibitors, according to results of two randomized phase 3 studies.Findings from the ATLAS-INH trial published in The Lancet revealed two-thirds of men with hemophilia A or B with inhibitors who received prophylactic fitusiran

Black Americans and minorities living with diabetes suffer higher rates of blindness, and now a new initiative may eventually provide them with an important resource.

Orelabrutinib led to significant reductions in brain lesions among relapsing-remitting MS patients in a Phase 2 trial, an analysis shows.

An international group of researchers, led by Dr. José Ángel Martínez-Climent at the Cima University of Navarra (Spain), has created mouse avatars of patients with multiple myeloma to study and develop personalized treatments against this blood cancer, the second most frequent hematological cancer and incurable in most cases. These artificial mice can mimic the genetic and immunological diversity of the origin and evolution of this disease in patients. This advance will allow researchers to d...

Neeraj Agarwal, MD, discusses preclinical data that supported the launch of the TALAPRO-2 trial and key efficacy and safety data on the use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer irrespective of homologous recombination repair mutational status.

An international group of researchers, led by Dr. José Ángel Martínez-Climent at the Cima University of Navarra, has created mouse avatars of patients with multiple myeloma to study and develop personalized treatments against this blood cancer, the second most frequent hematological cancer and incurable in most cases.

Regarding the forced vital capacity (FVC) and percent predicted FVC (FVC%) secondary outcomes in our TRAIL1 study,1 we wish to clarify the perceived inconsistency between the statistical model results and the raw data summaries, particularly for usual interstitial pneumonia. Although outcomes were secondary and subgroup analyses were not pre-planned, the statistical model estimated larger declines in placebo compared with pirfenidone for FVC and FVC%, a pattern not visually apparent in the raw d...